190 related articles for article (PubMed ID: 37561579)
1. A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome.
McDermott DH; Velez D; Cho E; Cowen EW; DiGiovanna JJ; Pastrana DV; Buck CB; Calvo KR; Gardner PJ; Rosenzweig SD; Stratton P; Merideth MA; Kim HJ; Brewer C; Katz JD; Kuhns DB; Malech HL; Follmann D; Fay MP; Murphy PM
J Clin Invest; 2023 Oct; 133(19):. PubMed ID: 37561579
[TBL] [Abstract][Full Text] [Related]
2. Plerixafor for the Treatment of WHIM Syndrome.
McDermott DH; Pastrana DV; Calvo KR; Pittaluga S; Velez D; Cho E; Liu Q; Trout HH; Neves JF; Gardner PJ; Bianchi DA; Blair EA; Landon EM; Silva SL; Buck CB; Murphy PM
N Engl J Med; 2019 Jan; 380(2):163-170. PubMed ID: 30625055
[TBL] [Abstract][Full Text] [Related]
3. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.
McDermott DH; Liu Q; Ulrick J; Kwatemaa N; Anaya-O'Brien S; Penzak SR; Filho JO; Priel DA; Kelly C; Garofalo M; Littel P; Marquesen MM; Hilligoss D; Decastro R; Fleisher TA; Kuhns DB; Malech HL; Murphy PM
Blood; 2011 Nov; 118(18):4957-62. PubMed ID: 21890643
[TBL] [Abstract][Full Text] [Related]
4. Clinical and genetic features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome.
Dotta L; Tassone L; Badolato R
Curr Mol Med; 2011 Jun; 11(4):317-25. PubMed ID: 21506920
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.
McDermott DH; Liu Q; Velez D; Lopez L; Anaya-O'Brien S; Ulrick J; Kwatemaa N; Starling J; Fleisher TA; Priel DA; Merideth MA; Giuntoli RL; Evbuomwan MO; Littel P; Marquesen MM; Hilligoss D; DeCastro R; Grimes GJ; Hwang ST; Pittaluga S; Calvo KR; Stratton P; Cowen EW; Kuhns DB; Malech HL; Murphy PM
Blood; 2014 Apr; 123(15):2308-16. PubMed ID: 24523241
[TBL] [Abstract][Full Text] [Related]
6. Severe CD8+ T Lymphopenia in WHIM Syndrome Caused by Selective Sequestration in Primary Immune Organs.
Majumdar S; Pontejo SM; Jaiswal H; Gao JL; Salancy A; Stassenko E; Yamane H; McDermott DH; Balabanian K; Bachelerie F; Murphy PM
J Immunol; 2023 Jun; 210(12):1913-1924. PubMed ID: 37133343
[TBL] [Abstract][Full Text] [Related]
7. The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.
Dale DC; Bolyard AA; Kelley ML; Westrup EC; Makaryan V; Aprikyan A; Wood B; Hsu FJ
Blood; 2011 Nov; 118(18):4963-6. PubMed ID: 21835955
[TBL] [Abstract][Full Text] [Related]
8. Genetics on a WHIM.
Al Ustwani O; Kurzrock R; Wetzler M
Br J Haematol; 2014 Jan; 164(1):15-23. PubMed ID: 24111611
[TBL] [Abstract][Full Text] [Related]
9. Tetralogy of fallot is an uncommon manifestation of warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Badolato R; Dotta L; Tassone L; Amendola G; Porta F; Locatelli F; Notarangelo LD; Bertrand Y; Bachelerie F; Donadieu J
J Pediatr; 2012 Oct; 161(4):763-5. PubMed ID: 22748845
[TBL] [Abstract][Full Text] [Related]
10. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome.
Dale DC; Firkin F; Bolyard AA; Kelley M; Makaryan V; Gorelick KJ; Ebrahim T; Garg V; Tang W; Jiang H; Skerlj R; Beaussant Cohen S
Blood; 2020 Dec; 136(26):2994-3003. PubMed ID: 32870250
[TBL] [Abstract][Full Text] [Related]
11. Plerixafor on a WHIM - Promise or Fantasy of a New CXCR4 Inhibitor for This Rare, but Important Syndrome?
Merati N; Sivachandran S; Jfri A; Ben-Shoshan M; Vinh DC; Popradi G; Litvinov IV
Skin Therapy Lett; 2022 Mar; 27(2):1-5. PubMed ID: 35385630
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcome of WHIM Syndrome in 18 Patients: High Risk of Lung Disease and HPV-Related Malignancies.
Dotta L; Notarangelo LD; Moratto D; Kumar R; Porta F; Soresina A; Lougaris V; Plebani A; Smith CIE; Norlin AC; Gòmez Raccio AC; Bubanska E; Bertolini P; Amendola G; Visentini M; Fiorilli M; Venuti A; Badolato R
J Allergy Clin Immunol Pract; 2019; 7(5):1568-1577. PubMed ID: 30716504
[TBL] [Abstract][Full Text] [Related]
13. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
14. A WHIM satisfactorily addressed.
Broxmeyer HE
Blood; 2014 Apr; 123(15):2286-8. PubMed ID: 24723677
[TBL] [Abstract][Full Text] [Related]
15. Cerebellar involvement in warts Hypogammaglobulinemia immunodeficiency myelokathexis patients: neuroimaging and clinical findings.
Galli J; Pinelli L; Micheletti S; Palumbo G; Notarangelo LD; Lougaris V; Dotta L; Fazzi E; Badolato R
Orphanet J Rare Dis; 2019 Feb; 14(1):61. PubMed ID: 30819232
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Hematologic Effects of Endotoxin in Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome Model Mice.
Majumdar S; Gao JL; Pontejo SM; Balabanian K; Bachelerie F; Murphy PM
Immunohorizons; 2022 Jul; 6(7):543-558. PubMed ID: 35882421
[TBL] [Abstract][Full Text] [Related]
17. AMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome.
McDermott DH; Lopez J; Deng F; Liu Q; Ojode T; Chen H; Ulrick J; Kwatemaa N; Kelly C; Anaya-O'Brien S; Garofalo M; Marquesen M; Hilligoss D; DeCastro R; Malech HL; Murphy PM
J Cell Mol Med; 2011 Oct; 15(10):2071-81. PubMed ID: 21070597
[TBL] [Abstract][Full Text] [Related]
18. Disease Progression of WHIM Syndrome in an International Cohort of 66 Pediatric and Adult Patients.
Geier CB; Ellison M; Cruz R; Pawar S; Leiss-Piller A; Zmajkovicova K; McNulty SM; Yilmaz M; Evans MO; Gordon S; Ujhazi B; Wiest I; Abolhassani H; Aghamohammadi A; Barmettler S; Bhar S; Bondarenko A; Bolyard AA; Buchbinder D; Cada M; Cavieres M; Connelly JA; Dale DC; Deordieva E; Dorsey MJ; Drysdale SB; Ehl S; Elfeky R; Fioredda F; Firkin F; Förster-Waldl E; Geng B; Goda V; Gonzalez-Granado L; Grunebaum E; Grzesk E; Henrickson SE; Hilfanova A; Hiwatari M; Imai C; Ip W; Jyonouchi S; Kanegane H; Kawahara Y; Khojah AM; Kim VH; Kojić M; Kołtan S; Krivan G; Langguth D; Lau YL; Leung D; Miano M; Mersyanova I; Mousallem T; Muskat M; Naoum FA; Noronha SA; Ouederni M; Ozono S; Richmond GW; Sakovich I; Salzer U; Schuetz C; Seeborg FO; Sharapova SO; Sockel K; Volokha A; von Bonin M; Warnatz K; Wegehaupt O; Weinberg GA; Wong KJ; Worth A; Yu H; Zharankova Y; Zhao X; Devlin L; Badarau A; Csomos K; Keszei M; Pereira J; Taveras AG; Beaussant-Cohen SL; Ong MS; Shcherbina A; Walter JE
J Clin Immunol; 2022 Nov; 42(8):1748-1765. PubMed ID: 35947323
[TBL] [Abstract][Full Text] [Related]
19. How I treat warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Badolato R; Donadieu J;
Blood; 2017 Dec; 130(23):2491-2498. PubMed ID: 29066537
[TBL] [Abstract][Full Text] [Related]
20. WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4.
Kawai T; Choi U; Cardwell L; DeRavin SS; Naumann N; Whiting-Theobald NL; Linton GF; Moon J; Murphy PM; Malech HL
Blood; 2007 Jan; 109(1):78-84. PubMed ID: 16946301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
